Bio-Sourcing
- Biotech or pharma, therapeutic R&D
The platform developed by BioSourcing enables the production of biotherapeutics at unprecedentedly low costs. Following the successful developments in the field of animal health, Bio-Sourcing is now also developing biotherapeutics for human health. Two biosimilars, adalimumab and trastuzumab, are already available for out-licensing and could be supplied at a price range in a few* dozen USD/gr of drug substance. (*may vary depending on product selected and other license terms)
Bio-Sourcing has been granted by the European Union (EIC accelerator grant) as one of the most innovative companies of 2024 Bio-Sourcing continues to develop its pipeline biosimilars for licensing, but can also develop your own biosimilar or original molecule.
In addition, Bio-Sourcing is developing an oral presentation of monoclonals, an invention that will be an obvious game changer for the treatment of monoclonals.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}